BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase

Dehui Zou, Shuhua Yi, Rui Cui, Wei Liu, Chengwen Li, Shizhen Zhong, Zhen Yu, Zengjun Li, Rui Lv, Kun Ru, Huijun Wang, Gang An, Yan Xu, Lugui Qiu

Research output: Contribution to journalArticle

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) of leukemic phase is a rare clinical manifestation, but is highly prevalent with central nervous system involvement (CNSI). Little is known about this rare clinical observation. Methods: We reviewed the clinical characteristics of 40 DLBCL patients with leukemic phase identified by flow cytometry and analyzed BCL2 and MYC aberrations by fluorescence in situ hybridization. Results: The median age of these 40 patients was 46 years (range, 15-75) with 19 men patients. All patients had bone marrow involvement, and fourteen (35.0%) had CNSI. There were respectively 14 patients (35.0%) had the BCL2 or MYC gain/amplification and nine of them (22.5%) simultaneously had both aberrations. Compared to those without CNSI, CNSI was found more commonly in male patients (71.4 vs. 34.6%, p = 0.046), in those with IPI scores of 4-5 (57.1% vs. 11.5%, p = 0.001), and in those with elevated serum LDH (100 vs. 61.5%, p = 0.007) and both MYC and BCL2 rearrangement (88.9 vs. 19.4%; p = 0.000). BCL2 and MYC rearrangements were the sole independent factor correlated with CNSI. Conclusion: It is possible that both BCL2 and MYC gene aberrations may contribute to the high incidence of CNSI observed in leukemic phase of patients with DLBCL.

LanguageEnglish (US)
Article number16
JournalBMC medical genetics
Volume18
Issue number1
DOIs
StatePublished - Feb 16 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Central Nervous System
Fluorescence In Situ Hybridization
Flow Cytometry
Bone Marrow
Observation
Incidence
Serum
Genes

Keywords

  • BCL2
  • Centre nervous system involvement
  • Diffuse large B cell lymphoma
  • Leukemic phase
  • MYC

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase. / Zou, Dehui; Yi, Shuhua; Cui, Rui; Liu, Wei; Li, Chengwen; Zhong, Shizhen; Yu, Zhen; Li, Zengjun; Lv, Rui; Ru, Kun; Wang, Huijun; An, Gang; Xu, Yan; Qiu, Lugui.

In: BMC medical genetics, Vol. 18, No. 1, 16, 16.02.2017.

Research output: Contribution to journalArticle

Zou, D, Yi, S, Cui, R, Liu, W, Li, C, Zhong, S, Yu, Z, Li, Z, Lv, R, Ru, K, Wang, H, An, G, Xu, Y & Qiu, L 2017, 'BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase' BMC medical genetics, vol 18, no. 1, 16. DOI: 10.1186/s12881-017-0381-z
Zou, Dehui ; Yi, Shuhua ; Cui, Rui ; Liu, Wei ; Li, Chengwen ; Zhong, Shizhen ; Yu, Zhen ; Li, Zengjun ; Lv, Rui ; Ru, Kun ; Wang, Huijun ; An, Gang ; Xu, Yan ; Qiu, Lugui. / BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase. In: BMC medical genetics. 2017 ; Vol. 18, No. 1.
@article{110f0e26db7846d28c14afb6d7d75cce,
title = "BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase",
abstract = "Background: Diffuse large B-cell lymphoma (DLBCL) of leukemic phase is a rare clinical manifestation, but is highly prevalent with central nervous system involvement (CNSI). Little is known about this rare clinical observation. Methods: We reviewed the clinical characteristics of 40 DLBCL patients with leukemic phase identified by flow cytometry and analyzed BCL2 and MYC aberrations by fluorescence in situ hybridization. Results: The median age of these 40 patients was 46 years (range, 15-75) with 19 men patients. All patients had bone marrow involvement, and fourteen (35.0{\%}) had CNSI. There were respectively 14 patients (35.0{\%}) had the BCL2 or MYC gain/amplification and nine of them (22.5{\%}) simultaneously had both aberrations. Compared to those without CNSI, CNSI was found more commonly in male patients (71.4 vs. 34.6{\%}, p = 0.046), in those with IPI scores of 4-5 (57.1{\%} vs. 11.5{\%}, p = 0.001), and in those with elevated serum LDH (100 vs. 61.5{\%}, p = 0.007) and both MYC and BCL2 rearrangement (88.9 vs. 19.4{\%}; p = 0.000). BCL2 and MYC rearrangements were the sole independent factor correlated with CNSI. Conclusion: It is possible that both BCL2 and MYC gene aberrations may contribute to the high incidence of CNSI observed in leukemic phase of patients with DLBCL.",
keywords = "BCL2, Centre nervous system involvement, Diffuse large B cell lymphoma, Leukemic phase, MYC",
author = "Dehui Zou and Shuhua Yi and Rui Cui and Wei Liu and Chengwen Li and Shizhen Zhong and Zhen Yu and Zengjun Li and Rui Lv and Kun Ru and Huijun Wang and Gang An and Yan Xu and Lugui Qiu",
year = "2017",
month = "2",
day = "16",
doi = "10.1186/s12881-017-0381-z",
language = "English (US)",
volume = "18",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase

AU - Zou,Dehui

AU - Yi,Shuhua

AU - Cui,Rui

AU - Liu,Wei

AU - Li,Chengwen

AU - Zhong,Shizhen

AU - Yu,Zhen

AU - Li,Zengjun

AU - Lv,Rui

AU - Ru,Kun

AU - Wang,Huijun

AU - An,Gang

AU - Xu,Yan

AU - Qiu,Lugui

PY - 2017/2/16

Y1 - 2017/2/16

N2 - Background: Diffuse large B-cell lymphoma (DLBCL) of leukemic phase is a rare clinical manifestation, but is highly prevalent with central nervous system involvement (CNSI). Little is known about this rare clinical observation. Methods: We reviewed the clinical characteristics of 40 DLBCL patients with leukemic phase identified by flow cytometry and analyzed BCL2 and MYC aberrations by fluorescence in situ hybridization. Results: The median age of these 40 patients was 46 years (range, 15-75) with 19 men patients. All patients had bone marrow involvement, and fourteen (35.0%) had CNSI. There were respectively 14 patients (35.0%) had the BCL2 or MYC gain/amplification and nine of them (22.5%) simultaneously had both aberrations. Compared to those without CNSI, CNSI was found more commonly in male patients (71.4 vs. 34.6%, p = 0.046), in those with IPI scores of 4-5 (57.1% vs. 11.5%, p = 0.001), and in those with elevated serum LDH (100 vs. 61.5%, p = 0.007) and both MYC and BCL2 rearrangement (88.9 vs. 19.4%; p = 0.000). BCL2 and MYC rearrangements were the sole independent factor correlated with CNSI. Conclusion: It is possible that both BCL2 and MYC gene aberrations may contribute to the high incidence of CNSI observed in leukemic phase of patients with DLBCL.

AB - Background: Diffuse large B-cell lymphoma (DLBCL) of leukemic phase is a rare clinical manifestation, but is highly prevalent with central nervous system involvement (CNSI). Little is known about this rare clinical observation. Methods: We reviewed the clinical characteristics of 40 DLBCL patients with leukemic phase identified by flow cytometry and analyzed BCL2 and MYC aberrations by fluorescence in situ hybridization. Results: The median age of these 40 patients was 46 years (range, 15-75) with 19 men patients. All patients had bone marrow involvement, and fourteen (35.0%) had CNSI. There were respectively 14 patients (35.0%) had the BCL2 or MYC gain/amplification and nine of them (22.5%) simultaneously had both aberrations. Compared to those without CNSI, CNSI was found more commonly in male patients (71.4 vs. 34.6%, p = 0.046), in those with IPI scores of 4-5 (57.1% vs. 11.5%, p = 0.001), and in those with elevated serum LDH (100 vs. 61.5%, p = 0.007) and both MYC and BCL2 rearrangement (88.9 vs. 19.4%; p = 0.000). BCL2 and MYC rearrangements were the sole independent factor correlated with CNSI. Conclusion: It is possible that both BCL2 and MYC gene aberrations may contribute to the high incidence of CNSI observed in leukemic phase of patients with DLBCL.

KW - BCL2

KW - Centre nervous system involvement

KW - Diffuse large B cell lymphoma

KW - Leukemic phase

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=85013057061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013057061&partnerID=8YFLogxK

U2 - 10.1186/s12881-017-0381-z

DO - 10.1186/s12881-017-0381-z

M3 - Article

VL - 18

JO - BMC Medical Genetics

T2 - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

IS - 1

M1 - 16

ER -